Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial

We describe the predictive value of BRCA1 gene status on trabectedin efficacy and found no correlation despite the mechanisms of action of this drug that rely on DNA repair systems.

• Publication year

  2018

• Venue

  Cancer Medicine

• Publication date

  2018-04-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cam4.1403PMID 29656586PMCID 5943428
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial

  2018cited by this paper
• Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

  2016cited by this paper
• BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients

  2015cited by this paper
• Trabectedin, a drug acting on both cancer cells and the tumour microenvironment

  2014cited by this paper
• Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study.

  2011cited by this paper
• Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743

  2007cited by this paper
• Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naïve patients

  2005cited by this paper

• Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products

  2024cites this paper
• Emerging predictive biomarkers in the management of bone and soft tissue sarcomas

  2023cites this paper
• The Role of Trabectedin in Soft Tissue Sarcoma

  2022cites this paper
• Homologous recombination repair deficiency as a therapeutic target in sarcoma.

  2020cites this paper
• Identification of potential prognostic small nucleolar RNA biomarkers for predicting overall survival in patients with sarcoma

  2020cites this paper
• Validation of Neutrophil Count as An Algorithm-Based Predictive Factor of Progression-Free Survival in Patients with Metastatic Soft Tissue Sarcomas Treated with Trabectedin

  2019cites this paper
• Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial

  2018cites this paper
• Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.

  2018cites this paper